Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya

niversity of Washington0 个研究点目标入组 60 人开始时间: 2024年1月18日最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•1)Willing and able to give written informed consent
•2)Age 18-30 years
•3)Female sex at birth
•4)HIV-seronegative, according to national HIV testing algorithm
•5)Has a current prescription for PrEP, according to the national guidelines of Kenya
•6)Able and willing to adhere to DOT dosing schedules

•1)Pregnant
•2)Breastfeeding a child
•3)Allergy to tetracycline class
•4)Current medications which may impact doxycycline metabolism or that are contraindicated with doxycycline, as per the prescribing information. These include systemic retinoids, barbiturates, carbamazepine, phenytoin, and warfarin.
•5)Active, clinically significant medical or psychiatric conditions that would interfere with study participation, at the discretion of the site investigator or designee.
•6)Prior enrollment in The dPEP Kenya Study

发起方

niversity of Washington